Leuven

• A study to investigate long-term follow-up in subjects who received BMN 270 in a prior BioMarin Clinical Trial with hemophilia A Ended recruitment
  2023-507749-27-00 6 2024-08-16 Hemophilia A
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended recruitment
  2023-505423-31-00 5 2024-08-08 advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
• Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al … Ended recruitment
  2023-505673-32-00 5 2024-08-05 Hypophosphatasia
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended recruitment
  2023-505746-25-00 4 2024-07-16 Cold agglutinin disease
• An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arte … Ended recruitment
  2023-506334-75-00 5 2024-07-12 Pulmonary Arterial Hypertension
• A study concerning the influence of tubal flushing with oil on pregnancy and live birth in women with fertility problems Ended recruitment
  2023-508896-35-00 6 2024-07-12 Infertile women with at least one patent tube at Hysterosalpingo-foam
• AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT … Ended recruitment
  2023-508130-33-00 9 2024-07-03 ADVANCED OR METASTATIC BREAST CANCER
• Treat-CMV Ended recruitment
  2022-500714-25-01 5 2024-06-19 congenital CMV infection
• A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patient … Ended recruitment
  2023-505316-37-00 4 2024-06-13 Post-Bariatric Hypoglycaemia
• A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma Ended recruitment
  2022-502661-23-00 7 2024-06-11 Relapsed/refractory B-cell non-Hodgkin lymphoma
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial) Ended recruitment
  2023-508166-15-00 6 2024-04-29 Ulcerative colitis (UC), Inflammatory bowel disease type unclassified
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi … Ended recruitment
  2023-506301-20-00 9 2024-04-15 Tuberous Sclerosis Complex (TSC)
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended recruitment
  2023-507333-17-00 5 2024-04-15 HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
• A study to see how well KarXT works and how well tolerated it is in participants with psychosis associated with Alzheimer’s disease. Ended recruitment
  2023-504416-16-00 5 2024-04-11 Psychosis Associated with Alzheimer’s Disease
• A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended recruitment
  2024-511472-32-00 5 2024-03-12 Crohn's Disease

Showing 625–648 of 1,135 trials